Therapeutic technology company Aethlon Medical Inc (Nasdaq:AEMD) stated on Thursday its net loss of USD1.21m (USD0.08 per share) for its fiscal third quarter ended 31 December 2017.

This is compared with a a slight higher net loss of USD1.206m (USD0.15 per share) for the December 2016 quarter.

Revenues of USD74,813 were collected for its fiscal third quarter ended 31 December 2017 under its contract with the National Cancer Institute. It did not have any government contract revenue in the December 2016 quarter.

Consolidated operating expenses for both the three month periods ended 31 December 2017 and 2016 were respectively USD1.24m, as increases in payroll and related expenses and in professional fees were largely offset by a decrease in general and administrative expenses.